CONNECTA Therapeutics secures €3.1M funding to advance CTH120, a TrkB modulator, into mid-stage trials for Fragile X syndrome treatment. Read more. CONNECTA TherapeuticsCTH120Fragile X syndromeTrkB modulatorclinical trial fundingrare diseaseneuroplasticityBarcelona biotechFXS treatmentneurodevelopmental disorder In parallel, CONNECTA is advancing preparations for a pediatric development programme under the FRAXCURE project, co-funded by the European Innovation Council. CEO Jordi Fàbrega said the company expects Phase IIa data in mid-2027 to represent a meaningful step in demonstrating CTH120's potential to address the underlying biology of the disease. Barcelona-based CONNECTA Therapeutics has closed a EUR 3.1 million (USD 3.4 million) financing round to support the clinical development of CTH120, its small-molecule neuroplasticity modulator in Fragile X syndrome (FXS), a rare neurodevelopmental disorder for which no approved targeted therapies currently exist. The round was led by Clave Capital, a new investor entering via its Innvierte Science Tech Clave Innohealth, F.C.R. fund, with participation from existing backers Inveready, CDTI Innvierte, and the Prous Institute for Biomedical Research. The financing follows a EUR 1.7 million seed round raised in 2020 led by Inveready and CDTI Innvierte, and complements substantial non-dilutive funding the company has secured over the same period, including a EUR 2.7 million grant from the Spanish Ministry of Science and the European Union's NextGeneration EU programme to fund the Phase IIa trial directly.

Original title: “CONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial”

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.

Original title: “Fragile X at a turning point: Breaking through the clinical bottleneck”

cerebellar gaba and executive function among adult female carriers of the fragile x messenger ribonucleoprotein 1 premutation a pilot study to examine neural underpinnings of the clinical phenotype

Original title: “Cerebellar GABA and executive function among adult female carriers of the fragile X messenger ribonucleoprotein 1 premutation: a pilot study to examine neural underpinnings of the clinical phenotype.”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Focus on Advancing Support and Transition with the Fragile X Online Registry With Acce

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

clinical trial designs for rare disorders a scoping review of the effectiveness of pharmacologic interventions in fragile x syndrome

Original title: “Clinical Trial Designs for Rare Disorders: A Scoping Review of the Effectiveness of Pharmacologic Interventions in Fragile X Syndrome.”

autopsy case with fragile x associated tremor ataxia syndrome presenting intranuclear inclusion bodies mainly in the limbic system

Original title: “An Autopsy Case With Fragile X-Associated Tremor/Ataxia Syndrome Presenting Intranuclear Inclusion Bodies Mainly in the Limbic System.”